Modeling Systemic Lupus Erythematosus Treatment Cost-Effectiveness Based on a Novel Lupus Low Disease Activity State Treat-to-Target Approach
Value in Health · 2026-11 · 29 (11) · 2025-2034
DOI: 10.1016/j.jval.2026.06.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-11. Verfasst von Maria Farris und 9 weiteren Autor:innen. Beteiligte Einrichtung: Market Access & Health Economics, AstraZeneca, Macquarie Park, NSW, Australia. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca PLC.
Abstract (Originalsprache)
OBJECTIVES: To demonstrate a new cost-effectiveness modeling approach in systemic lupus erythematosus (SLE), using treat-to-target health states defined by Lupus Low Disease Activity State (LLDAS). METHODS: A Markov Cohort State Transition Model evaluated the cost-effectiveness of anifrolumab plus standard of care (SOC) versus SOC in patients with moderate to severe SLE, by integrating the effects of disease activity and oral corticosteroid use on organ damage and mortality into 24 health states defined by LLDAS ("in LLDAS" or "Not in LLDAS") and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index scores (SDI 0 to ≥5). Transition probabilities, costs, and utilities were derived from observational cohort studies and phase 3 TULIP trial data. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were calculated (Australian dollars, 2023 prices), and supported by sensitivity analyses. RESULTS: Anifrolumab base-case results were $298 031 for discounted total costs and 9.099 for discounted total QALYs; SOC values were $280 426 and 8.952, respectively. There were incremental costs of $17 605 and QALYs of 0.147 with anifrolumab, leading to an ICER of $119 841/QALY. Probabilistic sensitivity analyses supported these findings. One-way sensitivity analyses identified LLDAS attainment rates at week 24 with anifrolumab vs SOC as the most influential parameter to the ICER, followed by mortality for patients "Not in LLDAS" vs "in LLDAS." Health-related quality of life and flares also influenced the ICER. CONCLUSIONS: Our model offers a simple and robust approach to assessing the cost-effectiveness of SLE treatments using validated and recommended treatment targets for patients with SLE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Market Access & Health Economics, AstraZeneca, Macquarie Park, NSW, Australia.
- Respiratory and Immunology, AstraZeneca, Macquarie Park, NSW, Australia.
- School of Clinical Sciences, Monash University, Melbourne, VIC, Australia.
- Dante Kemp Consulting Services, Merewether Heights, NSW, Australia; The South West Sydney Clinical Campuses, School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
- Centre for Inflammatory Diseases, School of Clinical Sciences, Sub-Faculty of Clinical and Molecular Medicine, Monash University, Melbourne, VIC, Australia.
- Faculty of Medicine and Health, School of Public Health, The University of Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Förderung
- AstraZeneca PLC
Zitieren
APA
Farris, M., Christensen, J., Golder, V., Kemp, D., Morand, E. F., Nikpour, M., Kandane-Rathnayake, R., Sierakowski, W., Tilden, D., & Lee, K. W. (2026). Modeling Systemic Lupus Erythematosus Treatment Cost-Effectiveness Based on a Novel Lupus Low Disease Activity State Treat-to-Target Approach. Value in Health, 29(11), 2025-2034. https://doi.org/10.1016/j.jval.2026.06.014
Vancouver
Farris M, Christensen J, Golder V, Kemp D, Morand EF, Nikpour M, et al. Modeling Systemic Lupus Erythematosus Treatment Cost-Effectiveness Based on a Novel Lupus Low Disease Activity State Treat-to-Target Approach. Value in Health. 2026;29(11):2025-2034. doi:10.1016/j.jval.2026.06.014
BibTeX
@article{Farris2026,
author = {Farris, Maria and Christensen, Jenna and Golder, Vera and Kemp, Dante and Morand, Eric F and Nikpour, Mandana and Kandane-Rathnayake, Rangi and Sierakowski, Will and Tilden, Dominic and Lee, Kai Wai},
title = {Modeling Systemic Lupus Erythematosus Treatment Cost-Effectiveness Based on a Novel Lupus Low Disease Activity State Treat-to-Target Approach},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {11},
pages = {2025--2034},
doi = {10.1016/j.jval.2026.06.014}
}
EUVIMED